Colorectal cancer (CRC) is a neoplasm with a high prevalence worldwide, with a multimodal treatment that includes a combination of chemotherapy, radiotherapy, and surgery in locally advanced stages with acceptable pathological complete response (pCR) rates, this has improved with the introduction of total neoadjuvant therapy (TNT) reaching pCR rates up to 37% in compare with classic neoadjuvant treatment (NAT) where pCR rates of around 20–25% are achieved. However, the patient population that benefits most from this therapy has not been determined, and there is a lack of biomarkers that can predict the course of the disease. Multiple biomarkers have been studied, ranging from hematological and molecular markers by imaging technique and combinations of them, with contradictory results that prevent their use in routine clinical practice. In this review, we evaluate the most robust prognostic biomarkers to be used in clinical practice, highlighting their advantages and disadvantages and emphasizing biomarker combinations and their predictive value.
结直肠癌（CRC）是一种全球高发恶性肿瘤，其局部进展期多模式治疗涵盖化疗、放疗与手术联合方案，可获得可观的病理完全缓解（pCR）率。随着全新辅助治疗（TNT）的应用，pCR率已提升至37%，而传统新辅助治疗（NAT）的pCR率约为20%-25%。然而，最能从此疗法中获益的患者群体尚未明确，且缺乏能够预测疾病进展的生物标志物。目前已有多种生物标志物被研究，涵盖血液学标志物、影像学技术检测的分子标志物及其组合，但研究结果相互矛盾，阻碍了其在常规临床实践中的应用。本综述旨在评估临床实践中最具稳健性的预后生物标志物，重点分析其优势与局限，并着重探讨生物标志物组合及其预测价值。
Landscape of Biomarkers and Pathologic Response in Rectal Cancer: Where We Stand?
肿瘤(癌症)患者之家